Amgen and Watson Pharmaceuticals will collaborate to develop and commercialize several oncology antibody biosimilar medicines. This collaboration “reflects the shared belief that the development and commercialization of biosimilar products will not follow a pure brand or generic model, and will require significant expertise, infrastructure, and investment to ensure safe, reliably supplied therapies for patients,” according to a joint statement. Amgen will assume primary responsibili...